Baxter Hlthcare Company Profile

What is the competitive landscape for BAXTER HLTHCARE, and when can generic versions of BAXTER HLTHCARE drugs launch?

BAXTER HLTHCARE has two hundred and eighteen approved drugs.

There are sixteen US patents protecting BAXTER HLTHCARE drugs. There are two tentative approvals on BAXTER HLTHCARE drugs.

There are thirty-seven patent family members on BAXTER HLTHCARE drugs in thirteen countries and three hundred supplementary protection certificates in fifteen countries.

Summary for Baxter Hlthcare

International Patents:	37
US Patents:	16
Tradenames:	330
Ingredients:	129
NDAs:	218

Drugs and US Patents for Baxter Hlthcare

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER	amino acids; dextrose	INJECTABLE;INJECTION	019520-009	Sep 23, 1988		DISCN	No	No
Baxter Hlthcare Corp	PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE	pantoprazole sodium	SOLUTION;INTRAVENOUS	217512-001	Feb 14, 2024		RX	Yes	Yes
Baxter Hlthcare Corp	BUTORPHANOL TARTRATE PRESERVATIVE FREE	butorphanol tartrate	INJECTABLE;INJECTION	075695-002	Oct 23, 2001		DISCN	No	No
Baxter Hlthcare	PENICILLIN G POTASSIUM IN PLASTIC CONTAINER	penicillin g potassium	INJECTABLE;INJECTION	050638-003	Jun 25, 1990		RX	Yes	Yes
Baxter Hlthcare	SODIUM CHLORIDE 3% IN PLASTIC CONTAINER	sodium chloride	INJECTABLE;INJECTION	019022-001	Nov 1, 1983	AP	RX	Yes	Yes
Baxter Hlthcare	PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER	amino acids	INJECTABLE;INJECTION	020849-001	Aug 26, 1998		RX	Yes	Yes
Baxter Hlthcare	TRAVERT 10% IN PLASTIC CONTAINER	invert sugar	INJECTABLE;INJECTION	016717-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Baxter Hlthcare

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-002	Feb 24, 1998	8,133,883
Baxter Hlthcare	EXTRANEAL	icodextrin	SOLUTION;INTRAPERITONEAL	021321-001	Dec 20, 2002	4,761,237
Baxter Hlthcare Corp	DOXIL (LIPOSOMAL)	doxorubicin hydrochloride	INJECTABLE, LIPOSOMAL;INJECTION	050718-001	Nov 17, 1995	5,213,804
Baxter Hlthcare	MESNEX	mesna	INJECTABLE;INTRAVENOUS	019884-001	Dec 30, 1988	5,696,172
Baxter Hlthcare Corp	DOXIL (LIPOSOMAL)	doxorubicin hydrochloride	INJECTABLE, LIPOSOMAL;INJECTION	050718-002	Jun 13, 2000	5,013,556
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-002	Dec 30, 1988	4,882,452
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-002	Dec 30, 1988	3,732,340

Paragraph IV (Patent) Challenges for BAXTER HLTHCARE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags		2014-01-31
	Inhalation	99.90%		2008-09-11

International Patents for Baxter Hlthcare Drugs

Country	Patent Number	Estimated Expiration
China	115243675
Israel	208956
Japan	6276828
China	101959508
Japan	6444548
Australia	2021233893
Eurasian Patent Organization	031355

Supplementary Protection Certificates for Baxter Hlthcare Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3141251	SPC/GB20/075	United Kingdom		PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS: POLYETHYLENE GLYCOL 3350, SODIUM SULPH; REGISTERED: IS IS/1/17/063/01 20171016; UK PL 20011/0040 20171016
2365988	2018C/006	Belgium		PRODUCT NAME: PATIROMER SORBITEX CALCIUM OF EERDER WELK ZOUT OF AFGELEIDE ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721
1856135	LUC00153	Luxembourg		PRODUCT NAME: FOSTAMATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, OU UN HYDRATE, SOLVATE OU N-OXYDE DE FOSTAMATINIB OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, EN PARTICULIER FOSTAMATINIB DISODIUM, EVENTUELLEMENT SOUS FORME D'HYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/19/1405 20200113
1856135	CA 2020 00018	Denmark		PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113
1713823	1490064-1	Sweden		PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
1307486	C 2012 018	Romania		PRODUCT NAME: PASIREOTIDA SI SARURILE ACCEPTABILE FARMACEUTIC ALEACESTEIACICLO[(4R)-4-(2-AMINOETILCARBAMOILOXI)-L-PROLIL-L-FENILGLICIL-D-TRIPTOFIL-L-LISIL-4-O-BENZIL-L-TIROSIL-L-FENILALANIL-); NATIONAL AUTHORISATION NUMBER: RO EU/1/12/753/001 - RO EU/1/12/753/012; DATE OF NATIONAL AUTHORISATION: 20120424; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/12/753/001 - EMEA EU/1/12/753/012; DATE OF FIRST AUTHORISATION IN EEA: 20120424
0253310	SPC/GB95/010	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Baxter Hlthcare
• Baxter Hlthcare Corp